New Combination Therapy For Advanced Kidney Cancer

Combination of an angiogenesis inhibitor and an immunotherapy agent has shown promise in treating advanced kidney cancer with no unexpected adverse effects in an early-phase clinical trial in patients who have not received prior treatment.

Related Links